04:09 AM EDT, 03/26/2025 (MT Newswires) -- Humacyte ( HUMA ) said late Tuesday it priced an underwritten public offering of 25 million shares at $2 per share for expected gross proceeds of $50 million.

The company said the proceeds from the offering, expected to close on Thursday, will support the commercialization of Symvess for vascular trauma, further product development, and general corporate needs.

Humacyte ( HUMA ) granted the underwriters a 30-day option to purchase an additional about 3.8 million shares.

The company's shares were down more than 23% in premarket activity Wednesday.